Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is designed to intervene in a known pathway that signals the body to store fat in adipose tissue. The study initiates in otherwise healthy obese subjects using single and multiple escalating doses of ARO-ALK7 monotherapy and is expected to progress rapidly to investigate combinations of ARO-ALK7 with tirzepatide in obese patients with and without type 2 diabetes.
'Arrowhead's two clinical stage RNAi-based obesity programs, ARO-ALK7 and ARO-INHBE, intervene in a known pathway that signals the body to store fat in adipose tissue. Both programs have strong genetic validation and promising results in preclinical studies, which suggest that silencing the respective genes may lead to reduced body weight and potentially preserve lean muscle mass resulting in improved body composition,' said James Hamilton, M.D., Chief Medical Officer and Head of R&D. 'This ongoing Phase 1/2a clinical study will evaluate single and multiple ascending doses of ARO-ALK7 as monotherapy in otherwise healthy obese volunteers as well as multiple doses in obese patients with or without type 2 diabetes in combination with incretin therapy.'
About ARO-ALK7
ARO-ALK7 is designed to silence adipocyte expression of the ACVR1C gene to reduce production of Activin receptor-like kinase 7 (ALK7), which acts as a receptor in a pathway that regulates energy homeostasis in adipose tissue. In large genetic datasets, reduced ACVR1C expression has been associated with healthier adipose distribution and reduced risk of obesity-related metabolic complications. In preclinical animal studies, ALK7 silencing in adipose tissue led to reduced body weight and fat mass with preservation of lean muscle. Treatment with investigational ARO-ALK7 has the potential to reduce visceral adiposity and improve lipid and glycemic parameters.
About the AROALK7-1001 Phase 1/2 Study
AROALK7-1001 ( NCT06937203 ) is a Phase 1/2a first-in-human dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-ALK7 in up to 90 adult volunteers with obesity. Part 1 of the study is designed to assess single and multiple doses of ARO-ALK7 monotherapy, and Part 2 of the study is designed to assess ARO-ALK7 in combination with tirzepatide, a subcutaneously administered GLP-1/GIP receptor co-agonist that has been approved in the United States and the European Union for management type 2 diabetes mellitus since 2022 and weight management since 2023/2024 respectively.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250602644854/en/
CONTACT: Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
[email protected]:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
[email protected]:
LifeSci Communications, LLC
Kendy Guarinoni, Ph.D.
724-910-9389
[email protected]
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH DIABETES GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Arrowhead Pharmaceuticals, Inc.
Copyright Business Wire 2025.
PUB: 06/02/2025 07:30 AM/DISC: 06/02/2025 07:28 AM
http://www.businesswire.com/news/home/20250602644854/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
SpaceX delivers four astronauts to the International Space Station just 15 hours after launch
CAPE CANAVERAL, Fla. (AP) — SpaceX delivered a fresh crew to the International Space Station on Saturday, making the trip in a quick 15 hours. The four U.S., Russian and Japanese astronauts pulled up in their SpaceX capsule after launching from NASA's Kennedy Space Center. They will spend at least six months at the orbiting lab, swapping places with colleagues up there since March. SpaceX will bring those four back as early as Wednesday. Moving in are NASA's Zena Cardman and Mike Fincke, Japan's Kimiya Yui and Russia's Oleg Platonov — each of whom had been originally assigned to other missions. Cardman and another astronaut were pulled from a SpaceX flight last year to make room for NASA's two stuck astronauts, Boeing Starliner test pilots Butch Wilmore and Suni Williams, whose space station stay went from one week to more than nine months. Fincke and Yui had been training for the next Starliner mission. But with Starliner grounded by thruster and other problems until 2026, the two switched to SpaceX. Platonov was bumped from the Soyuz launch lineup a couple of years ago because of an undisclosed illness. Their arrival temporarily puts the space station population at 11. While their taxi flight was speedy by U.S. standards, the Russians hold the record for the fastest trip to the space station — a lightning-fast three hours. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Solve the daily Crossword
Yahoo
14 minutes ago
- Yahoo
58-Year-Old Lottery Winner Tried To Strike A Deal With Teen Son, But Backed Out When The 19-Year-Old Wanted 80% —'I Didn't Realize How Greedy He Was'
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. We all daydream about winning the lottery. Maybe it's a beach house. Maybe it's early retirement. Or maybe—if you're a parent—you imagine setting your kid up for life. That's exactly what a 58-year-old father tried to do when he hit the jackpot with a $1,000-a-day-for-life prize. But instead of gratitude, he got a negotiation that made him rethink everything. In a viral Reddit post, the dad explained how he approached his 19-year-old son with a plan: he'd hand over the winning ticket, and in return, the son would give him half the money until the father passed. After that, the son would receive 100% of the daily payout for the rest of his life. Related: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share. Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's how you can earn passive income with just $10. Although he didn't spell out all the logic, the intent seemed clear: his son, being 19, had a much longer life expectancy and could benefit from the "for life" prize far longer than he could. The father was essentially trying to gift his son a lifetime of financial security—while covering himself with a fair 50/50 arrangement in the meantime. The teen's response? Not exactly a warm embrace. "He came back and said it wasn't really fair for me to want half," the dad wrote. "He said that I could live another 40 years. That he might need the money more and that I should take 20%." So the dad thought about it—and then signed the ticket and claimed the lump sum himself. He's now working with a lawyer to set his son up in other ways: college will be covered, a house fund will be waiting, and a trust is being arranged to ensure long-term support. Still, the son is angry—and so is the dad's ex, who apparently expected a cut too. Reddit, of course, had thoughts. A lot of them. "Dad is a sweetheart, son a greedy pig," one user wrote. Another called it "rage bait," adding, "No way is someone that greedy and s*****." One of the top-rated replies summed it up like this: "A 19-year-old kid tried to negotiate from $180K/year for doing nothing to $290K/year with zero leverage and was surprised when it blew up in his face." Some were quick to defend the father's pivot to the lump sum. "It was probably for the best," a commenter wrote. "Judging the son's character... the father was probably going to get hosed on that deal pretty much immediately." Others pointed out just how generous the original offer was. "If my father had offered me that deal, I would show up at his doorstep every morning with his cash, a dozen doughnuts, and his coffee exactly the way he likes it." For what it's worth, the dad isn't leaving his son high and dry—but he's not pretending the whole thing didn't sting. "I thought I was being smart, but I didn't realize how greedy he was," he wrote. In cases like this—where family, money, and long-term plans collide—it's often smart to bring in a professional. Even if you're not lucky enough to win the lottery, platforms like SmartAsset can connect you with financial advisors who help with everything from retirement planning to tax strategy to making sure your kids don't end up arguing over the inheritance. Whether you're setting up support for your kids, planning your estate, or just trying to avoid a financial decision you'll regret later, good advice can go a long way. Because giving your kid the golden goose? That's one thing. Watching him complain it's not laying fast enough—that's something else entirely. See Next: Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. It's no wonder Jeff Bezos holds over $250 million in art — this beloved alternative asset has outpaced the S&P 500 since 1995, delivering an average annual return of 11.4%. This article 58-Year-Old Lottery Winner Tried To Strike A Deal With Teen Son, But Backed Out When The 19-Year-Old Wanted 80% —'I Didn't Realize How Greedy He Was' originally appeared on Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
I missed Nvidia – could this be the next big US growth stock?
Let's be honest — most of us missed the boat on Nvidia (NASDAQ: NVDA). And by the time we realised just how vital graphics processing units (GPUs) would become to artificial intelligence (AI), the share price had already soared into the stratosphere. Over the past five years, the stock has climbed almost 1,600%. In the last six months alone, it's up almost 50%, adding over $1.5trn to its market value. It's now the most valuable company in the world, overtaking Microsoft and Apple in June. I have exposure to the stock through several ETFs and investment trusts, so I didn't entirely miss out on the action. But I certainly made nowhere near the gains I would have had I bought individual shares. Which makes me wonder, how did Nvidia get here, and what stock could be next? Crunching the numbers The numbers behind the hype are jaw-droppingly impressive. For the fiscal year ending January 2025, revenue reached $130bn, a staggering increase from $27bn just two years ago. Net income exploded from $4.3bn in 2022 to more than $70bn this year. And its margins are enormous — a return on equity of 115% and gross margins consistently above 70%. Yet despite the parabolic growth, I don't think it's entirely overvalued yet. In fact, I still think it's worth considering as a long-term investment. It's a world-class company with room to expand further and the global AI arms race is just getting started – with Nvidia at its core. Realistically, though, the biggest gains have already been made. Buying now means betting on continued dominance that may already be priced in, which is a risk. The stock trades at a price-to-earnings (P/E) ratio of 45 – not outrageous considering its growth, but not cheap either. So where should investors look if they want to catch the next killer growth stock before it becomes a trillion-dollar giant? Could SymphonyAI be next? One company on my radar is SymphonyAI, a private US firm reportedly preparing for a Nasdaq IPO later this year. It's not yet listed, but when it does go public, I'll be watching closely. Founded by billionaire Romesh Wadhwani, it specialises in applying AI to specific industry verticals – retail, finance, manufacturing, and healthcare. It doesn't build chips like Nvidia, but it builds the enterprise software that helps businesses harness AI to improve decision-making and productivity. Unlike many AI startups, SymphonyAI already has real revenues and customers. Its retail division serves over 1,200 brands, while its industrial arm works with giants like Nestlé and ArcelorMittal. While financials are still private, it reportedly generates hundreds of millions in annual revenue and is growing fast. If the IPO goes ahead this autumn, it could be one of the most closely watched tech listings of the year. Long-term mindset Nvidia's success was powered by timing, technology, and a growing reliance on data. It may still reward shareholders but the days of 10x returns are likely behind us. SymphonyAI might never reach Nvidia's heights but it could offer early-stage exposure to enterprise AI – the next leg of this growth story. If the valuation is right, it could turn out to be a once-in-a-decade opportunity. The post I missed Nvidia – could this be the next big US growth stock? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Mark Hartley has no position in any of the shares mentioned. The Motley Fool UK has recommended Apple, Microsoft, and Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
